

Roberto Latagliata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6100344/publications.pdf>

Version: 2024-02-01

351
papers

6,794
citations

61857

43
h-index

91712

69
g-index

356
all docs

356
docs citations

356
times ranked

5972
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiovascular Events and Intensity of Treatment in Polycythemia Vera. <i>New England Journal of Medicine</i> , 2013, 368, 22-33.	13.9	664
2	Elevated expression of IL-3R α in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. <i>Blood</i> , 2002, 100, 2980-2988.	0.6	272
3	Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. <i>British Journal of Haematology</i> , 1990, 75, 4-9.	1.2	182
4	AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. <i>Blood</i> , 2011, 117, 4716-4725.	0.6	173
5	Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. <i>Lancet Haematology</i> , 2017, 4, e127-e136.	2.2	132
6	Therapy-related myelodysplastic syndrome in acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. <i>Blood</i> , 2002, 99, 822-824.	0.6	125
7	Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database. <i>Journal of Clinical Oncology</i> , 2013, 31, 2671-2677.	0.8	121
8	Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. , 1998, 58, 105-109.		112
9	Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. <i>Blood</i> , 2002, 100, 2703-2707.	0.6	110
10	Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. <i>Leukemia</i> , 2007, 21, 79-83.	3.3	108
11	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020, 126, 1243-1252.	2.0	106
12	Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. <i>Annals of Hematology</i> , 2005, 84, 167-176.	0.8	105
13	CD 7 positive acute myeloid leukaemia: a subtype associated with cell immaturity. <i>British Journal of Haematology</i> , 1989, 73, 480-485.	1.2	103
14	A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 750-755.	0.9	92
15	Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2002, 116, 576-581.	1.2	80
16	Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17). <i>Journal of Clinical Oncology</i> , 2013, 31, 4424-4430.	0.8	78
17	Identification of risk factors in atypical chronic myeloid leukemia. <i>Haematologica</i> , 2006, 91, 1566-8.	1.7	78
18	Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. <i>American Journal of Hematology</i> , 2009, 84, 636-640.	2.0	75

#	ARTICLE	IF	CITATIONS
19	Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. <i>Leukemia</i> , 2003, 17, 1085-1090.	3.3	74
20	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	0.6	72
21	Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. <i>Haematologica</i> , 2011, 96, 696-702.	1.7	64
22	Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. <i>Blood</i> , 2012, 119, 49-54.	0.6	63
23	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. <i>Oncotarget</i> , 2017, 8, 79073-79086.	0.8	63
24	Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. <i>European Journal of Haematology</i> , 2005, 74, 121-123.	1.1	62
25	Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. <i>Leukemia</i> , 2015, 29, 1344-1349.	3.3	62
26	Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. <i>American Journal of Hematology</i> , 2017, 92, 37-41.	2.0	62
27	Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. <i>Haematologica</i> , 2012, 97, 560-567.	1.7	61
28	Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. <i>Hematological Oncology</i> , 2013, 31, 103-109.	0.8	59
29	Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. <i>Leukemia Research</i> , 2007, 31, 1770-1772.	0.4	58
30	Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. <i>Haematologica</i> , 2011, 96, 1457-1461.	1.7	58
31	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. <i>Haematologica</i> , 2019, 104, 1589-1596.	1.7	58
32	Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. <i>Haematologica</i> , 2007, 92, 101-105.	1.7	57
33	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. <i>Leukemia</i> , 2020, 34, 2260-2261.	3.3	57
34	Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. <i>British Journal of Haematology</i> , 2008, 143, 681-689.	1.2	54
35	Real-life results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia. <i>Leukemia Research</i> , 2010, 34, 1472-1475.	0.4	53
36	JAK2V617F allele burden ≥450% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy. <i>Leukemia</i> , 2016, 30, 1772-1775.	3.3	50

#	ARTICLE	IF	CITATIONS
37	Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation. <i>Haematologica</i> , 2010, 95, 853-854.	1.7	49
38	FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis. <i>Haematologica</i> , 2013, 98, e161-e163.	1.7	49
39	Iron toxicity "Its effect on the bone marrow. <i>Blood Reviews</i> , 2018, 32, 473-479.	2.8	46
40	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018, 36, 561-569.	0.8	46
41	Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia. <i>Leukemia</i> , 1993, 7, 549-52.	3.3	46
42	Ocular side effects in chronic myeloid leukemia patients treated with imatinib. <i>Leukemia Research</i> , 2008, 32, 1022-1025.	0.4	45
43	Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib. <i>European Journal of Haematology</i> , 2005, 74, 89-90.	1.1	44
44	A long-term study of young patients with essential thrombocythemia treated with anagrelide. <i>Haematologica</i> , 2004, 89, 1306-13.	1.7	44
45	Survival of elderly patients with acute myeloid leukemia. <i>Haematologica</i> , 2004, 89, 296-302.	1.7	43
46	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021, 11, 4.	2.8	41
47	Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms. <i>Cancer</i> , 2012, 118, 404-409.	2.0	40
48	Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC). <i>Supportive Care in Cancer</i> , 2015, 23, 3289-3295.	1.0	39
49	Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen. <i>Leukemia</i> , 2003, 17, 925-930.	3.3	38
50	Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in Elderly acute myeloid leukaemia patients. <i>Hematological Oncology</i> , 2009, 27, 148-153.	0.8	38
51	Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. <i>Leukemia Research</i> , 2010, 34, 143-147.	0.4	37
52	Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. <i>Leukemia and Lymphoma</i> , 2010, 51, 1007-1014.	0.6	36
53	Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients. <i>Leukemia Research</i> , 2011, 35, 159-162.	0.4	36
54	Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study. <i>Drugs and Aging</i> , 2013, 30, 629-637.	1.3	36

#	ARTICLE	IF	CITATIONS
55	Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971â€“1991). <i>Leukemia</i> , 1998, 12, 869-874.	3.3	35
56	Thrombosis and survival in essential thrombocythemia: A regional study of 1,144 patients. <i>American Journal of Hematology</i> , 2014, 89, 542-546.	2.0	33
57	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. <i>Annals of Hematology</i> , 2018, 97, 95-100.	0.8	32
58	Deferasirox treatment for myelodysplastic syndromes: â€œreal-lifeâ€ efficacy and safety in a single-institution patient population. <i>Annals of Hematology</i> , 2012, 91, 1345-1349.	0.8	31
59	Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a realâ€world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. <i>European Journal of Haematology</i> , 2016, 96, 344-351.	1.1	31
60	Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. <i>Annals of Oncology</i> , 2006, 17, 281-285.	0.6	30
61	Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. <i>Leukemia Research</i> , 2014, 38, 1173-1176.	0.4	30
62	Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. <i>Leukemia and Lymphoma</i> , 2013, 54, 2458-2465.	0.6	29
63	Efficacy and safety of ruxolitinib in intermediateâ€1 IPSS risk myelofibrosis patients: Results from an independent study. <i>Hematological Oncology</i> , 2018, 36, 285-290.	0.8	29
64	Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. <i>Leukemia Research</i> , 2011, 35, 1164-1169.	0.4	28
65	Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients. <i>American Journal of Hematology</i> , 2016, 91, 318-321.	2.0	28
66	Immunophenotyping of acute myeloid leukaemia: Relevance of analysing different lineage-associated markers. <i>Blut</i> , 1989, 58, 235-240.	1.2	27
67	Management of infective complications in patients with advanced hematologic malignancies in home care. <i>Leukemia</i> , 1997, 11, 1807-1812.	3.3	26
68	The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged >60 years. <i>Annals of Oncology</i> , 1997, 8, 1273-1275.	0.6	25
69	Changes in <i>RPS14</i> expression levels during lenalidomide treatment in Lowâ€and Intermediateâ€1â€risk myelodysplastic syndromes with chromosome 5q deletion. <i>European Journal of Haematology</i> , 2010, 85, 231-235.	1.1	25
70	Azacitidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. <i>Leukemia Research</i> , 2015, 39, 801-804.	0.4	25
71	Realâ€world experience with decitabine as a firstâ€line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy. <i>Hematological Oncology</i> , 2019, 37, 447-455.	0.8	25
72	Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit. <i>Haematologica</i> , 1999, 84, 814-9.	1.7	25

#	ARTICLE	IF	CITATIONS
73	Treatment of long-lasting priapism in chronic myeloid leukemia at onset. <i>Annals of Hematology</i> , 2000, 79, 644-645.	0.8	24
74	Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML). <i>BioDrugs</i> , 2014, 28, 17-26.	2.2	24
75	Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. <i>Neoplasia</i> , 2016, 18, 536-540.	2.3	24
76	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <i>Seminars in Hematology</i> , 2018, 55, 248-255.	1.8	24
77	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. <i>Oncotarget</i> , 2016, 7, 80083-80090.	0.8	24
78	Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution. <i>Haematologica</i> , 2004, 89, 866-8.	1.7	24
79	Myelodysplastic syndromes in patients under 50 years old: a single institution experience. <i>Leukemia Research</i> , 2005, 29, 749-754.	0.4	23
80	Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. <i>Annals of Hematology</i> , 2013, 92, 25-32.	0.8	23
81	Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells. <i>Annals of Hematology</i> , 2014, 93, 1819-1823.	0.8	23
82	Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. <i>Leukemia Research</i> , 2014, 38, 194-197.	0.4	23
83	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. <i>Leukemia Research</i> , 2018, 74, 86-88.	0.4	23
84	Intraventricular thrombosis during all-trans retinoic acid treatment in acute promyelocytic leukemia. <i>Leukemia</i> , 2001, 15, 1311-1313.	3.3	22
85	GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. <i>British Journal of Haematology</i> , 2011, 154, 564-568.	1.2	22
86	Deferasirox chelation therapy in patients with transfusion-dependent <scp>MDS</scp>: a "real-world" report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata. <i>European Journal of Haematology</i> , 2015, 95, 52-56.	1.1	22
87	Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia. <i>Annals of Hematology</i> , 2007, 86, 263-270.	0.8	21
88	Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. <i>Leukemia Research</i> , 2005, 29, 287-291.	0.4	20
89	Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia. <i>Haematologica</i> , 2011, 96, 1390-1391.	1.7	20
90	ITACA: A new validated international erythropoietic stimulating agent response score that further refines the predictive power of previous scoring systems. <i>American Journal of Hematology</i> , 2017, 92, 1037-1046.	2.0	20

#	ARTICLE	IF	CITATIONS
91	Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. <i>Annals of Hematology</i> , 2018, 97, 1797-1802.	0.8	20
92	Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients. <i>Supportive Care in Cancer</i> , 2020, 28, 4193-4199.	1.0	20
93	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2022, 196, 559-565.	1.2	20
94	Is Recombinant Human Erythropoietin Treatment in Myelodysplastic Syndromes Worthwhile?. <i>Leukemia and Lymphoma</i> , 1993, 9, 79-83.	0.6	19
95	Acute myeloid leukemia in the elderly: â€per aspera ad astraâ€™?. <i>Leukemia Research</i> , 1999, 23, 603-613.	0.4	19
96	The EUTOS score identifies chronic myeloid leukaemia patients with poor prognosis treated with imatinib first or second line. <i>Leukemia Research</i> , 2012, 36, e209-e210.	0.4	19
97	Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib. <i>Cancer Letters</i> , 2013, 333, 32-35.	3.2	19
98	Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase. <i>European Journal of Haematology</i> , 2016, 96, 643-649.	1.1	19
99	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021, 193, 356-368.	1.2	19
100	Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. <i>Oncotarget</i> , 2018, 9, 7534-7540.	0.8	19
101	Twice-Weekly High-Dose rHuEpo for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndromes. <i>Acta Haematologica</i> , 2008, 120, 104-107.	0.7	18
102	Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence. <i>Cancer Medicine</i> , 2015, 4, 1789-1797.	1.3	18
103	Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events. <i>Annals of Hematology</i> , 2018, 97, 1803-1808.	0.8	18
104	Outpatient management of acute promyelocytic leukemia after consolidation chemotherapy. <i>Leukemia</i> , 1999, 13, 514-517.	3.3	17
105	Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia. <i>Leukemia</i> , 2004, 18, 182-182.	3.3	17
106	Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2006, 30, 178-182.	0.4	17
107	Late Relapses in Acute Promyelocytic Leukaemia. <i>Acta Haematologica</i> , 2007, 117, 106-108.	0.7	17
108	Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin. <i>Haematologica</i> , 2008, 93, 1918-1920.	1.7	17

#	ARTICLE	IF	CITATIONS
109	Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients. <i>Leukemia and Lymphoma</i> , 2010, 51, 783-788.	0.6	17
110	Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. <i>Annals of Hematology</i> , 2019, 98, 2329-2338.	0.8	17
111	Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome. <i>Hematological Oncology</i> , 2019, 37, 652-654.	0.8	17
112	Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission. <i>Haematologica</i> , 2001, 86, 814-20.	1.7	17
113	Polycythaemia vera and cerebral blood flow: a preliminary study with transcranial Doppler. <i>Journal of Internal Medicine</i> , 1993, 234, 599-602.	2.7	16
114	Cytotoxic effectors activated by low-dose IL-2 plus IL-12 lyse IL-2-resistant autologous acute myeloid leukaemia blasts. <i>British Journal of Haematology</i> , 1998, 101, 150-157.	1.2	16
115	Granulocytic Sarcoma with Breast and Skin Presentation: A Report of a Case Successfully Treated by Local Radiation and Systemic Chemotherapy. <i>Acta Haematologica</i> , 2000, 104, 34-37.	0.7	16
116	Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age. <i>Annals of Hematology</i> , 2015, 94, 195-200.	0.8	15
117	Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. <i>Blood Reviews</i> , 2019, 34, 16-25.	2.8	15
118	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020, 38, 372-380.	0.8	15
119	Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 2328-2332.	0.6	14
120	Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizations. <i>Leukemia Research</i> , 2009, 33, e134-e136.	0.4	14
121	The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, E661-E664.	2.0	14
122	Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. <i>Annals of Hematology</i> , 2017, 96, 387-391.	0.8	14
123	Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. <i>Hematological Oncology</i> , 2019, 37, 291-295.	0.8	14
124	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021, 127, 2657-2665.	2.0	14
125	Conservative treatment for patients over 80 years with acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2002, 71, 256-259.	2.0	13
126	Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenetic response after interferon-alpha results in a very high complete molecular response rate. <i>Leukemia Research</i> , 2008, 32, 255-261.	0.4	13

#	ARTICLE	IF	CITATIONS
127	The risk of infections in patients with myelodysplastic syndromes in 2016. Expert Review of Hematology, 2016, 9, 607-614.	1.0	13
128	Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response. Leukemia and Lymphoma, 2016, 57, 99-102.	0.6	13
129	Impact of exclusion criteria for the DASISION and ENESTnd trials in the frontâ€line treatment of a â€realâ€lifeâ€™ patient population with chronic myeloid leukaemia. Hematological Oncology, 2017, 35, 232-236.	0.8	13
130	Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. Haematologica, 2004, 89, 615-7.	1.7	13
131	Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose. Hematological Oncology, 2010, 28, 89-92.	0.8	12
132	Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. Leukemia Research, 2011, 35, 504-507.	0.4	12
133	Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. Annals of Hematology, 2013, 92, 179-183.	0.8	12
134	Erythropoietin treatment of idiopathic myelofibrosis. Haematologica, 1993, 78, 371-3.	1.7	12
135	Spontaneous remission in adult patients with de novo myelodysplastic syndrome: a possible event. Haematologica, 2001, 86, 1277-80.	1.7	12
136	Etoposide, intermediate-dose cytarabine and carboplatin (VAC): A combination therapy for the blastic phase of chronic myelogenous leukemia. Annals of Oncology, 1997, 8, 175-179.	0.6	11
137	High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias. Annals of Hematology, 2003, 82, 476-480.	0.8	11
138	Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation. Leukemia Research, 2005, 29, 33-39.	0.4	11
139	Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis. Leukemia Research, 2015, 39, 314-317.	0.4	11
140	Comparison of <i>JAK2</i>^{V617F}â€positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology. Hematological Oncology, 2018, 36, 269-275.	0.8	11
141	Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience. Annals of Hematology, 2020, 99, 2405-2416.	0.8	11
142	PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count. Journal of Thrombosis and Thrombolysis, 2020, 49, 426-430.	1.0	11
143	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. Blood, 2018, 132, 4277-4277.	0.6	11
144	Coranaric thrombotic events in acute promyelocytic leukemia during all-trans retinoic acid treatment: a role for adhesion molecules over expression?. Leukemia, 1999, 13, 312-313.	3.3	10

#	ARTICLE	IF	CITATIONS
145	Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up. American Journal of Hematology, 2010, 85, 375-377.	2.0	10
146	Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib. American Journal of Hematology, 2015, 90, 105-108.	2.0	10
147	Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life. Annals of Hematology, 2019, 98, 1891-1904.	0.8	10
148	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. Annals of Hematology, 2019, 98, 889-896.	0.8	10
149	Long Term Follow-Up of the Gimema GSI 103 AMLE Randomized Trial: Daunoxome Seems To Improve Disease-Free Survival (DFS) of Elderly Patients with Acute Myelogenous Leukemia (AML).. Blood, 2006, 108, 1979-1979.	0.6	10
150	Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS). Blood, 2012, 120, 923-923.	0.6	10
151	Treatment of high-risk myelodysplastic syndromes with lymphoblastoid alpha interferon. British Journal of Haematology, 1996, 95, 364-367.	1.2	9
152	Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a "grey zone" at 3, 6 and 12-months identifies chronic myeloid leukaemia patients who need early intervention. British Journal of Haematology, 2011, 152, 119-121.	1.2	9
153	Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia. Cancer Medicine, 2017, 6, 1233-1239.	1.3	9
154	High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia. Thrombosis Research, 2017, 156, 168-171.	0.8	9
155	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. Hematological Oncology, 2021, 39, 409-418.	0.8	9
156	MEC (Mitoxantrone, Etoposide and Intermediate Dose Cytarabine): An Effective Induction Regimen for Previously Untreated Acute Non-Lymphocytic Leukemia. Leukemia and Lymphoma, 1995, 19, 447-451.	0.6	8
157	Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients. Leukemia and Lymphoma, 2008, 49, 994-997.	0.6	8
158	Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. Annals of Hematology, 2019, 98, 1919-1925.	0.8	8
159	Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?. Leukemia Research, 2019, 76, 65-69.	0.4	8
160	Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors. Hematological Oncology, 2021, 39, 401-408.	0.8	8
161	Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group". European Journal of Haematology, 2020, 105, 335-343.	1.1	8
162	Molecular and cytogenetic remission in a case of subtype M4E acute myelogenous leukemia with minimal monochemotherapy: high sensitivity or spontaneous remission?. European Journal of Haematology, 2000, 65, 203-206.	1.1	7

#	ARTICLE	IF	CITATIONS
163	BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results. <i>Bone Marrow Transplantation</i> , 2005, 36, 83-84.	1.3	7
164	Management of the 2009 A/H1N1 Influenza Pandemic in Patients with Hematologic Diseases: A Prospective Experience at an Italian Center. <i>Acta Haematologica</i> , 2011, 126, 1-7.	0.7	7
165	Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study. <i>Annals of Hematology</i> , 2014, 93, 1413-1420.	0.8	7
166	Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study. <i>Annals of Hematology</i> , 2016, 95, 1059-1065.	0.8	7
167	Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life. <i>American Journal of Hematology</i> , 2017, 92, E668-E670.	2.0	7
168	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. <i>British Journal of Haematology</i> , 2018, 183, 35-46.	1.2	7
169	SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. <i>HemaSphere</i> , 2020, 4, e483.	1.2	7
170	Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial. <i>Blood</i> , 2019, 134, 3000-3000.	0.6	7
171	Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors. <i>Blood</i> , 2019, 134, 1649-1649.	0.6	7
172	Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial. <i>Blood</i> , 2015, 126, 91-91.	0.6	7
173	From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox. <i>Frontiers in Oncology</i> , 2021, 11, 752192.	1.3	7
174	Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study. <i>British Journal of Haematology</i> , 2022, 197, 190-200.	1.2	7
175	Acute nonlymphocytic leukemia in the elderly: results of a retrospective study. <i>Haematologica</i> , 1989, 74, 167-71.	1.7	7
176	Pregnancy in patients with myelodysplastic syndromes (MDS). <i>Leukemia Research</i> , 2008, 32, 1605-1607.	0.4	6
177	Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal. <i>Leukemia Research</i> , 2009, 33, 391-394.	0.4	6
178	Unexpected Erythroid and Cytogenetic Responses After Discontinuation of a Short Course of Lenalidomide As a Result of Severe Skin Rash in a Patient With 5q Syndrome. <i>Journal of Clinical Oncology</i> , 2011, 29, e402-e403.	0.8	6
179	Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experience. <i>Leukemia and Lymphoma</i> , 2012, 53, 2439-2443.	0.6	6
180	MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013045.	0.5	6

#	ARTICLE	IF	CITATIONS
181	Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid. <i>British Journal of Haematology</i> , 2014, 167, 428-430.	1.2	6
182	Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront. <i>Leukemia and Lymphoma</i> , 2015, 56, 2206-2207.	0.6	6
183	Dasatinib first-line: Multicentric Italian experience outside clinical trials. <i>Leukemia Research</i> , 2016, 40, 24-29.	0.4	6
184	Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. <i>Hematological Oncology</i> , 2020, 38, 189-196.	0.8	6
185	New dead/H-box helicase gene (ddx41) mutation in an Italian family with recurrent leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2280-2283.	0.6	6
186	Simultaneous Occurrence of Large B-Cell non-Hodgkin Lymphoma and Myelodysplastic Syndrome Rapidly Evolving into Acute Myeloblastic Leukemia. <i>Leukemia and Lymphoma</i> , 1996, 21, 339-341.	0.6	5
187	Complete Clearance of Ph+ Metaphases after 3 Months Is a Very Early Indicator of Good Response to Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia. <i>Acta Haematologica</i> , 2013, 129, 126-134.	0.7	5
188	Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia. <i>Hematological Oncology</i> , 2017, 35, 804-809.	0.8	5
189	Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. <i>Annals of Hematology</i> , 2019, 98, 1933-1936.	0.8	5
190	PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study. <i>Blood</i> , 2005, 106, 2600-2600.	0.6	5
191	Hematologic alterations and early mortality in a cohort of HIV positive African patients. <i>PLoS ONE</i> , 2020, 15, e0242068.	1.1	5
192	Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion. <i>Annals of Hematology</i> , 2012, 91, 309-310.	0.8	4
193	Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up. <i>Leukemia and Lymphoma</i> , 2021, 62, 1026-1027.	0.6	4
194	Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2021, 100, 1213-1219.	0.8	4
195	Bone Marrow Biopsy and Aspirate Evaluation in 90 Patients with Essential Thrombocythemia Treated with PEG Interferon alpha-2b. Preliminary Results. <i>Blood</i> , 2004, 104, 1523-1523.	0.6	4
196	Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis. <i>Blood</i> , 2016, 128, 1128-1128.	0.6	4
197	Are ET and PV Patients Two Similar Populations As Concern Thrombotic Risk Factors?. <i>Blood</i> , 2015, 126, 2811-2811.	0.6	4
198	High doses of ara-C and m-AMSA in the treatment of refractory acute non lymphocytic leukemia. <i>Haematologica</i> , 1990, 75, 249-51.	1.7	4

#	ARTICLE	IF	CITATIONS
199	Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report. <i>Haematologica</i> , 1993, 78, 123-6.	1.7	4
200	Bisantrene in Relapsed and Refractory Acute Myelogenous Leukemia. <i>Leukemia and Lymphoma</i> , 1993, 9, 217-220.	0.6	3
201	Is aggressive chemotherapy the best choice for patients with acute nonlymphocytic leukemia after myelodysplastic syndromes?. <i>Leukemia Research</i> , 1995, 19, 213-217.	0.4	3
202	Intracardiac Thrombus in a Patient with Autoimmune Hemolytic Anemia Leading to a Diagnosis of Antiphospholipid Syndrome. <i>Acta Haematologica</i> , 2002, 107, 170-172.	0.7	3
203	Refractory Anaemia with Excess of Blasts in Transformation Re-Evaluated with the WHO Criteria: Identification of Subgroups with Different Survival. <i>Acta Haematologica</i> , 2007, 117, 221-225.	0.7	3
204	Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols. <i>Leukemia Research</i> , 2013, 37, 383-385.	0.4	3
205	Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?. <i>Hematological Oncology</i> , 2015, 33, 48-51.	0.8	3
206	A POPULATION-BASED STUDY ON MYELODYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017046.	0.5	3
207	Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib. <i>British Journal of Haematology</i> , 2018, 181, 275-278.	1.2	3
208	The IPSS-R has prognostic impact in untreated patients with MDS del(5q). <i>Leukemia Research</i> , 2018, 72, 27-33.	0.4	3
209	Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. <i>European Journal of Haematology</i> , 2018, 101, 578-584.	1.1	3
210	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019, 37, 418-423.	0.8	3
211	A Large-Scale Trial Testing the Intensity of Cytoreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera (CYTO-PV trial). <i>Blood</i> , 2012, 120, 4-4.	0.6	3
212	Incidence of Early Thrombosis in Myeloproliferative Neoplasms (MPN): A Prospective Analysis from the Gruppo Laziale of Ph-Negative MPN. <i>Blood</i> , 2016, 128, 1951-1951.	0.6	3
213	Utility of procalcitonin and C-reactive protein as predictors of Gram-negative bacteremia in febrile hematological outpatients. <i>Supportive Care in Cancer</i> , 2022, 30, 4303-4314.	1.0	3
214	Acute Myeloblastic Leukemia Secondary to Myelodysplasia (MDS-AML): A Comparison of Remission Induction with Three Drugs Versus Standard Two-Drugs Induction. <i>Leukemia and Lymphoma</i> , 2000, 36, 539-541.	0.6	2
215	Apoptosis Susceptibility and Cell-Cycle Distribution in Cells from Myelodysplastic Syndrome Patients: Modulatory In-Vitro Effects of G-CSF and Interferon- γ . <i>Leukemia and Lymphoma</i> , 2004, 45, 1437-1443.	0.6	2
216	Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results. <i>International Journal of Hematology</i> , 2009, 90, 486-491.	0.7	2

#	ARTICLE	IF	CITATIONS
217	Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide. <i>Leukemia Research</i> , 2011, 35, e69-e70.	0.4	2
218	Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile. <i>American Journal of Hematology</i> , 2014, 89, 565-565.	2.0	2
219	Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>American Journal of Hematology</i> , 2015, 90, E181-2.	2.0	2
220	Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up. <i>Leukemia Research</i> , 2018, 69, 18-23.	0.4	2
221	Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2018, 71, 89-91.	0.4	2
222	Incidence of Clinically Significant (≥ 10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib. <i>Oncology Research and Treatment</i> , 2019, 42, 660-664.	0.8	2
223	Management and outcome of 11 pregnancies in women with polycythemia vera. <i>Leukemia Research</i> , 2019, 81, 25-26.	0.4	2
224	Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance. <i>Leukemia and Lymphoma</i> , 2020, 61, 3476-3483.	0.6	2
225	Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia. <i>European Journal of Haematology</i> , 2020, 105, 286-291.	1.1	2
226	Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2020, 99, 2773-2777.	0.8	2
227	Very late acute myeloid leukemia relapse: clinical features, treatment and outcome. <i>Leukemia and Lymphoma</i> , 2021, 62, 1022-1025.	0.6	2
228	Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. <i>Acta Oncologica</i> , 2021, 60, 1520-1526.	0.8	2
229	Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. <i>Acta Oncologica</i> , 2021, 60, 1527-1533.	0.8	2
230	Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience. <i>Blood</i> , 2019, 134, 839-839.	0.6	2
231	Low-Dose Dasatinib as Front-Line Therapy for Elderly (> 60 Years) Patients with CML. <i>Blood</i> , 2010, 116, 2293-2293.	0.6	2
232	Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia. <i>Blood</i> , 2011, 118, 3783-3783.	0.6	2
233	Risk Factors for Infections in Myelofibrosis: Role of Disease Status and Treatment. A Study on 507 Patients. <i>Blood</i> , 2015, 126, 1606-1606.	0.6	2
234	Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis. <i>Blood</i> , 2016, 128, 4251-4251.	0.6	2

#	ARTICLE	IF	CITATIONS
235	Hammersmith Score Is Able to Identify Chronic Myeloid Leukemia Patients with Poor Prognosis Before Treatment with Second-Generation TKIs.. Blood, 2010, 116, 3409-3409.	0.6	2
236	Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. Blood, 2019, 134, 4174-4174.	0.6	2
237	Thymopentin in the Treatment of Myelodysplastic Syndromes. Acta Haematologica, 1991, 86, 115-115.	0.7	1
238	A case-control study of the effects of hydroxyurea on circulating cortisol levels in patients with acute myelogenous leukemia and chronic myeloproliferative disorders. Pharmacological Research, 2000, 42, 389-392.	3.1	1
239	Association of Hydroxyurea to Imatinib Is Effective in Patients with Chronic Myelogenous Leukemia Resistant to Imatinib Alone.. Blood, 2004, 104, 4693-4693.	0.6	1
240	Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results.. Blood, 2005, 106, 4962-4962.	0.6	1
241	Circulating MUC1 Levels (CA15.3) in Myeloproliferative Disorders (MPD). Blood, 2008, 112, 5237-5237.	0.6	1
242	Increases In Mirna-145 and Mirna-146a Expression In Patients with IPSS Lower-Risk Myelodysplastic Syndromes and Del(5q) Treated with Lenalidomide.. Blood, 2010, 116, 3631-3631.	0.6	1
243	Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?. Blood, 2011, 118, 2770-2770.	0.6	1
244	Treatment with Erythropoietic Stimulating Agents in IPSS Lower Risk MDS: Outcome Comparison Between 5q- and Non 5q- MDS Cases. Blood, 2011, 118, 2799-2799.	0.6	1
245	How Epidemiology of Polycythemia Vera Has Changed in the Last 10 Years: Results From the Whole Prospective Cohort of Patients in Cyto-PV Trial As Compared with Eclap Prospective Cohort. Blood, 2012, 120, 1748-1748.	0.6	1
246	Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a "Real-life" Patient Population With Chronic Myelogenous Leukemia?. Blood, 2013, 122, 4002-4002.	0.6	1
247	Event-Free Survival According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: The Younger, the Later, the Worse?. Blood, 2015, 126, 4038-4038.	0.6	1
248	Cost Description on a Cohort of 659 Patients with Adult MDS Included into the Italian Lazio Region Registry (the GROM-L). Blood, 2015, 126, 5237-5237.	0.6	1
249	Incidence of Severe (> 10g/dl) Chronic Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib and Role of Erythropoietin Therapy. Blood, 2016, 128, 1903-1903.	0.6	1
250	Long-Term Results of the GIMEMA LAP AIDA 0493 Amended Protocol in Elderly Patients with Acute Promyelocytic Leukemia (APL).. Blood, 2005, 106, 885-885.	0.6	1
251	Darbepoetin for the Treatment of Anemia of Myelodysplastic Syndromes: Efficacy and Improvements in Quality of Life.. Blood, 2006, 108, 2667-2667.	0.6	1
252	Quality of Life Scores Have a Prognostic Significance In Elderly AML Patients.. Blood, 2008, 112, 1949-1949.	0.6	1

#	ARTICLE	IF	CITATIONS
253	Differences in Haematological and Non Haematological Toxicity during Treatment with Imatinib in Early and Late Chronic Phase Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2008, 112, 4281-4281.	0.6	1
254	Lenalidomide for the Treatment of Low- and Int-1-Risk MDS with Del(5q): Efficacy and Quality of Life Study. <i>Blood</i> , 2009, 114, 2763-2763.	0.6	1
255	Results of Imatinib Dose Escalation After 36 Months of Follow-up in Chronic Myeloid Leukemia Patients with Failure or Sub-Optimal Response According to 2006 European Leukemia Net (ELN) Criteria. <i>Blood</i> , 2009, 114, 3302-3302.	0.6	1
256	MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients. <i>Blood</i> , 2011, 118, 3793-3793.	0.6	1
257	Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elderly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival. <i>Blood</i> , 2011, 118, 2751-2751.	0.6	1
258	The Experience of Gruppo Laziale for the Study of Ph-, Chronic Myeloproliferative Syndromes in the Treatment of Myeloproliferative Neoplasms in Blastic Phase with Azacytidine. <i>Blood</i> , 2014, 124, 3164-3164.	0.6	1
259	Application of the International Prognostic Score of Thrombosis for Essential Thrombocytemia (ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms. <i>Blood</i> , 2015, 126, 2821-2821.	0.6	1
260	Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment. <i>Blood</i> , 2016, 128, 5544-5544.	0.6	1
261	Deferasirox in the Treatment of Iron Overload during Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2016, 128, 5465-5465.	0.6	1
262	Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019, 134, 4184-4184.	0.6	1
263	Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols. <i>Blood</i> , 2019, 134, 3845-3845.	0.6	1
264	Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study. <i>Blood</i> , 2021, 138, 3617-3617.	0.6	1
265	Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Polycythemia Vera Resistant/Intolerant to Hydroxyurea. <i>Blood</i> , 2021, 138, 2581-2581.	0.6	1
266	64 Myelodysplastic syndromes (MDS) in patients aged >20 and <40 years. <i>Leukemia Research</i> , 1997, 21, S17.	0.4	0
267	Familial occurrence of myelodysplastic syndrome with del(5q). <i>Leukemia and Lymphoma</i> , 2011, 52, 1143-1145.	0.6	0
268	Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients. <i>American Journal of Hematology</i> , 2015, 90, E95-E96.	2.0	0
269	Erythropoietin treatment in patients with myelodysplastic syndromes and type 2 diabetes. <i>Diabetes</i> , 2015, 7, 493-496.		
270	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e328-e333.	0.2	0

#	ARTICLE	IF	CITATIONS
271	Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 2261-2266.	0.6	0
272	Therapy-Related Myelodysplastic Syndrome (sMDS) /Acute Myelogenous Leukemia (sAML) in Acute Promyelocytic Leukemia (APL) Patients with Long-Lasting Molecular Remission: The GIMEMA Experience.. <i>Blood</i> , 2005, 106, 884-884.	0.6	0
273	Increased Risk of Thrombotic Events in Patients with Acute Promyelocytic Leukemia (APL) Receiving ATRA Treatment: Does It Correlate with CD2 and FLT3 Expression?.. <i>Blood</i> , 2005, 106, 887-887.	0.6	0
274	Risk Factors for Cardiovascular Events in Myeloproliferative Syndromes.. <i>Blood</i> , 2006, 108, 3595-3595.	0.6	0
275	Quality of Life in Elderly Patients with Acute Myeloid Leukemia.. <i>Blood</i> , 2006, 108, 3320-3320.	0.6	0
276	Impact of Age in the Outcome of Patients with Chronic Myeloid Leukemia in Late Chronic Phase: Clinical and Molecular Results of a Phase II Study of the GIMEMA CML Working Party.. <i>Blood</i> , 2006, 108, 4805-4805.	0.6	0
277	Imatinib Mesylate Therapy in Late Ph+ Chronic Myeloid Leukemia Patients in Stable Complete Cytogenetic Response after Interferon-Alpha Results in a Very High Complete Molecular Response Rate.. <i>Blood</i> , 2006, 108, 2158-2158.	0.6	0
278	JAK2 (V617F) Mutation Levels and Marrow Fibrosis in Patients Affected by Budd-Chiari Syndrome and Non-Cirrhotic Extra-Hepatic Portal Vein Obstruction.. <i>Blood</i> , 2007, 110, 4652-4652.	0.6	0
279	Changes in Gene Expression Profiles during Treatment with Erythropoetic Growth Factors in Myelodysplastic Syndromes.. <i>Blood</i> , 2007, 110, 4609-4609.	0.6	0
280	Favourable Outcome of Pregnancy in Essential Thrombocythemia (ET) Patients Treated with Interferon Alpha. A Report from the Registro Italiano Trombocitemia (RIT).. <i>Blood</i> , 2007, 110, 2549-2549.	0.6	0
281	Decisional Flow with a Score System To Start Platelet-Lowering Treatment in Patients with Essential Thrombocythemia (ET): Long-Term Results.. <i>Blood</i> , 2007, 110, 4636-4636.	0.6	0
282	Dasatinib in the Treatment of CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib. <i>Blood</i> , 2008, 112, 4253-4253.	0.6	0
283	Cytoreductive Combined Therapy in Essential Thrombocythemia Patients: Report of the Registro Italiano Trombocitemia (RIT). <i>Blood</i> , 2008, 112, 5243-5243.	0.6	0
284	Cytoreductive Therapeutic Approach in the Essential Thrombocythemia (ET) Patients of the Registro Italiano Trombocitemia (RIT): Preliminary Data. <i>Blood</i> , 2008, 112, 5248-5248.	0.6	0
285	Prognostic Relevance of Retrospective WHO Re-Classification in 650 MDS Patients Diagnosed by FAB Criteria. <i>Blood</i> , 2008, 112, 5097-5097.	0.6	0
286	Comorbidities and FLT3 Abnormalities as Independent Prognostic Indicators of Survival in Elderly Acute Myeloid Leukemia Patients. <i>Blood</i> , 2008, 112, 3983-3983.	0.6	0
287	ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS AGED > 70 Years.. <i>Blood</i> , 2009, 114, 4160-4160.	0.6	0
288	The Dose and the duration of frontline therapy with Imatinib does not affect response to Dasatinib in Imatinib-Resistant or -intolerant patients with chronic myeloid leukemia (CML). Results from a real Life-Based Italian Multicenter retrospective study on 124 Patients.. <i>Blood</i> , 2009, 114, 1124-1124.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Imatinib as Front-Line Treatment in Chronic Myelogenous Leukemia: How Important is the Achievement of Complete Cytogenetic Response after 3 Months?. Blood, 2009, 114, 4271-4271.	0.6	0
290	Clinical Usefulness and Safety of Peripherally-Inserted Central Catethers (PICC) in Hematological Patients.. Blood, 2009, 114, 4545-4545.	0.6	0
291	Clinical Results in Patients with Primary and Secondary Myelofibrosis Treated with Monthly Cycles of Oral Melphalan.. Blood, 2009, 114, 4985-4985.	0.6	0
292	Gene Expression Changes in Bone Marrow of MDS Patients with Del(5q) During Lenalidomide Treatment.. Blood, 2009, 114, 2622-2622.	0.6	0
293	Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib.. Blood, 2009, 114, 2211-2211.	0.6	0
294	Minor Erythroid Response and Decreased WT1 Expression After Proteasome Inhibition by Bortezomib in Myelodysplastic Syndromes (GIMEMA MDS0104 Phase II Trial).. Blood, 2009, 114, 1777-1777.	0.6	0
295	Myelodysplastic Syndrome Patients Younger Than 50 Years: Epidemiological Data and Clinical Features. Blood, 2010, 116, 4976-4976.	0.6	0
296	Retrospective Application of European LeukemiaNet Provisional Criteria for Second-Generation TKI Chronic Myeloid Leukemia. Blood, 2010, 116, 2270-2270.	0.6	0
297	Skin Toxicity of Hydroxyurea In Ph- Myeloproliferative Neoplasms: Incidence and Clinical Features. Blood, 2010, 116, 3077-3077.	0.6	0
298	Bone Marrow Immunological Changes During Treatment with Lenalidomide In Low and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5Q). Blood, 2010, 116, 2927-2927.	0.6	0
299	A Retrospective Epidemiological Analysis of 1572 Cases of Ph1- Myeloproliferative Neoplasms (MPNs) From 9 Centers In the Latium: Preliminary Results. Blood, 2010, 116, 5065-5065.	0.6	0
300	Imatinib In Very Elderly CML Patients: What Can We Achieve?.. Blood, 2010, 116, 1229-1229.	0.6	0
301	Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment. Blood, 2011, 118, 4445-4445.	0.6	0
302	Clinical Follow-up of Patients with Myeloproliferative Neoplasms Presenting Skin Ulcers During Treatment with Hydroxyurea. Blood, 2011, 118, 5157-5157.	0.6	0
303	Clinical Features of Idiopathic Erythrocytosis Compared to Polycythemia Vera JAK-2 V617F Positive and Negative Patients. Blood, 2011, 118, 5172-5172.	0.6	0
304	APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS. Blood, 2011, 118, 1686-1686.	0.6	0
305	Risk Factors for Thrombosis Vary According to Age in Patients with Essential Thrombocythemia: a Retrospective Analysis of 1090 Patients from the "Gruppo Laziale SMPC Ph Negative". Blood, 2011, 118, 3854-3854.	0.6	0
306	Increased Body Mass Index Correlates with Higher Risk of Disease Relapse and Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia Treated with Aida Protocols. Blood, 2011, 118, 4866-4866.	0.6	0

#	ARTICLE	IF	CITATIONS
307	The Role of Previous Thrombotic Events in Patients with Essential Thrombocythemia: The Earlier the Worse?. Blood, 2012, 120, 5062-5062.	0.6	0
308	Response to Erythropoietin in a Multicentric Real-Life Cohort of Myelodysplastic Patients: The Grom Experience. Blood, 2012, 120, 4958-4958.	0.6	0
309	Delayed Cytogenetic Response and Reduced Rate of Major Molecular Response Associated to Increased Body Mass Index At Baseline in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib.. Blood, 2012, 120, 2784-2784.	0.6	0
310	Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib. Blood, 2012, 120, 3769-3769.	0.6	0
311	Long-Term Follow-up of Chronic Phase Chronic Myeloid Leukemia Patients Who Failed Interferon Alpha and Switched to Imatinib. Blood, 2012, 120, 3742-3742.	0.6	0
312	FLT3-ITD Internal Tandem Duplication Confers Poor Prognosis In Patients With Acute Promyelocytic Leukemia Treated With The AIDA Protocols. Long-Term Follow-Up Analysis. Blood, 2013, 122, 1336-1336.	0.6	0
313	Real-Life Efficacy Of Azacitidine In Myelodysplastic Syndromes According To IPSS Cytogenetic Profile. Blood, 2013, 122, 5229-5229.	0.6	0
314	Deferasirox In The Treatment Of Iron Overload During Myeloproliferative Neoplasms (MPN). Blood, 2013, 122, 1594-1594.	0.6	0
315	Prognostic Factors Associated To Achievement Of Complete Or Partial Response In MDS Patients Treated With Azacitidine Outside Clinical Trials. Blood, 2013, 122, 5203-5203.	0.6	0
316	Prognostic Factors for Thrombosis-Free Survival and Overall Survival in Polycythemia Vera: A Retrospective Analysis of 623 Patients Series with Long Follow-up. Blood, 2014, 124, 1855-1855.	0.6	0
317	Real-life Frontline Dasatinib Treatment in Unselected Elderly Patients with Chronic Myeloid Leukemia. Blood, 2014, 124, 5530-5530.	0.6	0
318	Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid Leukemia. Blood, 2014, 124, 3687-3687.	0.6	0
319	Incidence of Infectious Complications in MDS/AML Patients Treated with Azacitidine By the Italian Cooperative Groups Gruppo Romano MDS (GROM) and Basilicata MDS Registry. Blood, 2014, 124, 3265-3265.	0.6	0
320	Role of CD133 As a Marker of Previous Myelodysplasia in De Novo Elderly Patients with Acute Myeloid Leukemia. Blood, 2014, 124, 1063-1063.	0.6	0
321	Mutations and Long-Term Outcome of 217 Young Patients with Essential Thrombocythemia or Early Primary Myelofibrosis. Blood, 2014, 124, 3190-3190.	0.6	0
322	Acute Myeloid Leukemia Patients with an Undefined Genetic Profile at Diagnosis: Clinical and Prognostic Aspects. Blood, 2014, 124, 5326-5326.	0.6	0
323	Hematological Improvement during Deferasirox Treatment in Patients with Myeloproliferative Neoplasms (MPN). Blood, 2014, 124, 3189-3189.	0.6	0
324	JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome. Blood, 2015, 126, 1614-1614.	0.6	0

#	ARTICLE	IF	CITATIONS
325	The Platelet COUNT at Diagnosis of Essential Thrombocythemia Is a Prognostic Factor for Thrombosis-Free Survival: Retrospective Analysis on 1201 Patients. <i>Blood</i> , 2015, 126, 2815-2815.	0.6	0
326	Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response. <i>Blood</i> , 2015, 126, 1582-1582.	0.6	0
327	Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline. <i>Blood</i> , 2015, 126, 1598-1598.	0.6	0
328	Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis. <i>Blood</i> , 2016, 128, 5464-5464.	0.6	0
329	Latium (Italy) Epidemiology of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs) from 2011 to 2015: A Prospective Analysis from Gruppo Laziale of Ph Negative MPN. <i>Blood</i> , 2016, 128, 5473-5473.	0.6	0
330	Essential Thrombocythemia: A Comparison of Overall and Thrombosis Free Survival in Two Discrete Periods of the First Decade of 2000. a Retrospective Analysis. <i>Blood</i> , 2016, 128, 5469-5469.	0.6	0
331	Young CML Patients Treated Frontline with Imatinib or Second Generation TKIs: Clinical Characteristics and Outcome. <i>Blood</i> , 2016, 128, 3078-3078.	0.6	0
332	Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?. <i>Blood</i> , 2018, 132, 1746-1746.	0.6	0
333	Presentation and Outcome of 199 Patients with 2016 Who Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. <i>Blood</i> , 2018, 132, 3052-3052.	0.6	0
334	Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice. <i>Blood</i> , 2018, 132, 5518-5518.	0.6	0
335	Overall Survival and Response Rates after a 10-Year Follow-up of Chronic Myeloid Leukemia Patients in Chronic Phase Treated with Imatinib in a Real-Life Practice. <i>Blood</i> , 2018, 132, 1741-1741.	0.6	0
336	Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?. <i>Blood</i> , 2018, 132, 5516-5516.	0.6	0
337	Frontline Treatment with Dasatinib in Very Elderly Patients (> 75 Years) with Chronic Myeloid Leukemia: Is It Feasible?. <i>Blood</i> , 2018, 132, 5438-5438.	0.6	0
338	Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI). <i>Blood</i> , 2018, 132, 4312-4312.	0.6	0
339	Management and Outcome of 11 Pregnancies in Women with Polycythemia Vera. <i>Blood</i> , 2018, 132, 5471-5471.	0.6	0
340	Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 3021-3021.	0.6	0
341	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of Who 2001 Versus Who 2008/2016 Criteria in a Large Single Center Cohort. <i>Blood</i> , 2018, 132, 5464-5464.	0.6	0
342	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. <i>Blood</i> , 2019, 134, 4166-4166.	0.6	0

#	ARTICLE	IF	CITATIONS
343	Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement. <i>Blood</i> , 2019, 134, 3010-3010.	0.6	0
344	Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality. <i>American Journal of Blood Research</i> , 2021, 11, 417-426.	0.6	0
345	Nursing Management of Frail Patients with Hematologic Malignancies during COVID-19 Pandemia in the Viterbo Domiciliary Care Unit: Data Analysis from March 2020 to March 2021. <i>Blood</i> , 2021, 138, 3022-3022.	0.6	0
346	Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study. <i>Blood</i> , 2021, 138, 1487-1487.	0.6	0
347	Hemoglobin Changes during Long-Lasting Frontline Treatment with Tyrosine-Kinase Inhibitors in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2021, 138, 1486-1486.	0.6	0
348	NGS Evaluation of the Ego-MDS Trial: Preliminary Analysis of Eltrombopag for Thrombocytopenia of Low-Risk MDS. <i>Blood</i> , 2021, 138, 1516-1516.	0.6	0
349	Erythropoietin in myelodysplastic syndromes: durable response in a young patient. <i>Haematologica</i> , 1996, 81, 381-2.	1.7	0
350	Prolonged low doses of oral etoposide may be effective in individual patients with advanced lymphoproliferative disorders refractory to aggressive chemotherapy. <i>Haematologica</i> , 1997, 82, 126-7.	1.7	0
351	Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical "Biological Entity?". <i>Journal of Clinical Medicine</i> , 2022, 11, 2596.	1.0	0